Patients with moderate to severe ulcerative colitis who were treated with 2 mg of etrasimod a day showed significant improvements, according to a study presented at the ACG Annual Scientific Meeting. Patients achieved "statistically significant and clinical meaningful differences in all primary and secondary endpoints" as well as improved exploratory endpoints, said William Sandborn, MD, of the University of California at San Diego, who added that the study highlights the need for a Phase III clinical development program.
Treatment with etrasimod may ease ulcerative colitis symptoms
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.